T 2471/17 of 21.02.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T247117.20220221
- Date of decision
- 21 February 2022
- Case number
- T 2471/17
- Petition for review of
- -
- Application number
- 10182213.8
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Use of HIF Alpha stabilizers for enhancing erythropoiesis
- Applicant name
- Fibrogen, Inc.
- Opponent name
- Akebia Therapeutics, Inc.
GLAXO GROUP LIMITED
Bayer Intellectual Property GmbH/Bayer Pharma
Aktiengesellschaft/Bayer Animal Health GmbH
GlaxoSmithKline UK Limited - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)
- Keywords
- Amendments - added subject-matter (yes)
Prohibition of reformatio in peius - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.